News & Events

  • April 19, 2012

    Ellenoff Grossman & Schole LLP was the premier sponsor at Deal Flow Media's CrowdFunding Conference, in New York City.  Douglas S. Ellenoff, a member of the Firm, opened the conference with his keynote address focusing on the outlook of the CrowdFunding Market.  Sarah E. Williams, also a member of the Firm, moderated the panel: Understanding Policy Issues vs. Securities Rules if you're in the CrowdFunding Business.
     

  • April 18, 2012

    Titan Pharmaceuticals,Inc. announced the closing of their Registered Direct offering in the amount of $5,540,000.  EG&S acted as counsel to the placement agent.
     

  • April 18, 2012

    ParkerVision announced the closing of their Registered Direct in the amount of $1,963,501.  EG&S acted as counsel to the placement agent.
     

  • April 11, 2012

    DARA BioSciences, Inc. announced the closing of their Registered Direct offering in the amount of $10,250,000.  EG&S acted as counsel to the placement agent.
     

  • April 11, 2012

    Dipexium Pharmaceuticals, LLC, a private biotechnology company, closed a venture private placement of Series A membership interests and warrants in an amount of over $500,000. EG&S acted as counsel to Dipexium.

  • April 04, 2012

    Ellenoff Grossman & Schole LLP was ranked #1 for placement agent representation in PIPE transactions (by number of transactions) for the first quarter of 2012.

    Click here to view the rankings

  • April 04, 2012

    Morria Biopharmaceuticals, PLC announced the closing of their PIPE offering in the amount of $1,100,000.  EG&S acted as counsel to the investor.
     

  • March 30, 2012

    Epicept Corporation announced the closing of their Registered Direct offering in the amount of $1,065,000. EG&S acted as counsel to the placement agent.

  • March 30, 2012

    Elephant Talk Communications Corp. (Amex: ETAK) issued certain Senior Secured Convertible Notes in the principal amount of $8,800,000 to accredited investors. EG&S acted as issuer's counsel.
     

  • March 30, 2012

    NeoStem, Inc. (NYSE Amex: NBS) sold 15,000,000 units at $0.40 per unit with $6 million in gross proceeds in an underwritten offering pursuant to the NeoStem's shelf registration statement . Each unit consists of one share of common stock and a warrant to purchase one share of common stock with a per share exercise price of $0.51. Maxim Group LLC acted as sole bookrunner. NeoStem has also granted Maxim a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. EG&S acted as Maxim’s counsel.

  • March 28, 2012

    EDAP TMS S.A. announced the closing of their Registered Direct in the amount of $5,625,000. EG&S acted as counsel to the placement agent.
     

  • March 28, 2012

    Oncosec Medical Incorporated announced the closing of their Registered Direct offering in the amount of $7,750,000. EG&S acted as counsel to the placement agent.

  • March 26, 2012

    BGS Acquisition Corp. announced the closing of their initial public offering in the amount of $40,000,000. EG&S acted as counsel to BGS Acquisition Corp.

  • March 22, 2012

    Marina Biotech, Inc. announced the closing of their Registered Direct offering in the amount of $1,200,002. EG&S acted as counsel to the placement agent.
     

  • March 21, 2012

    GeoVax, Inc. announced the closing of their PIPE offering in the amount of $2,200,000. EG&S acted as counsel to the placement agent.
     

  • March 09, 2012

    Proteonomix, Inc. announced the closing of their PIPE offering in the amount of $3,804,991. EG&S acted as counsel to the placement agent.
     

  • March 07, 2012

    Barry I. Grossman, a member of the Firm was invited by Capital Link to participate in their 3rd Annual Greek Shipping Forum in Athens, Greece.  Mr. Grossman spoke on Alternative Public Offerings and what Companies Need to Know.

    Click here to view the Presentation

  • March 06, 2012

    The Supreme Court, State of New York, entered a permanent injunction staying a FINRA arbitration brought by an individual against a Broker-Dealer. The individual alleged that the Broker-Dealer's former employee had sold him shares in a private placement. On the motion, EG&S successfully showed that the individual had never been a customer of the firm and that it was not likely that he could show that he was even a "customer" of the employee or had a sound basis to believe he was. Partner Adrienne Ward led the effort, with assistance from associate Holly Froum.

     

  • February 22, 2012

    People’s Liberation, Inc. announced the closing of their Private Placement in the amount of $11,500,000. EG&S acted as counsel to the Investor.

  • February 20, 2012

    Superconductor Technologies Inc. announced the closing of their Registered Direct offering in the amount of $4,563,535. EG&S acted as counsel to the placement agent.
     

  • February 15, 2012

    Cardium Therapeutics, Inc. announced the closing of their Registered Direct in the amount of $5,000,000. EG&S acted as counsel to the placement agent.
     

  • February 14, 2012

    Apps Genius Corp announced the closing of their Registered Direct offering in the amount of $1,000,000.  EG&S acted as counsel to the placement agent.

  • February 10, 2012

    Neuralstem, Inc. announced the closing of their Registered Direct offering in the amount of $5,050,000.  EG&S acted as counsel to the placement agent.
     

  • February 10, 2012

    EpiCept Corporation announced the closing of their Registered Direct offering in the amount of $2,000,000. EG&S acted as counsel to the placement agent.
     

  • February 09, 2012

    Advaxis, Inc. announced the closing of their PIPE offering in the amount of $1,047,500. EG&S acted as counsel to the placement agent.